Available to mentor
Dr. Joanna Spencer-Segal is a physician-scientist in the Department of Internal Medicine and the Michigan Neuroscience Institute. A neuroendocrinologist, she cares for patients with disorders of pituitary hormone function in the Multidisciplinary Pituitary Program. She runs a translational neuroendocrinology research program focused on improving our understanding of how circulating hormones control neural function and motivated behaviors, and the specific neural circuits that direct systemic endocrine function.
-
Postdoctoral Research Fellow, Molecular and Behavioral NeuroscienceUniversity of Michigan–Ann Arbor, Internal Medicine, 2017
-
Fellowship , Metabolism, Endocrinology and DiabetesUniversity of Michigan–Ann Arbor, Internal Medicine, 2016
-
Center MemberEisenberg Family Depression Center
The Spencer-Segal lab focuses on the neural circuits that govern emotional behaviors, both innately and in response to stress. Many of the regions of and circuits in the brain that play a role in emotional behavior also influence the stress response. Stress hormones also act directly on brain regions that influence mood and related behaviors. The Spencer-Segal laboratory is disentangling the neural circuits that direct stressor-specific neuroendocrine and behavioral responses.
Another area of research involves the neuroendocrinology of critical illness and sepsis. Critical illness is often fatal, and survivors face an uphill battle that frequently includes mental health challenges such as anxiety, depression, post-traumatic stress disorder, and cognitive dysfunction. Our lab is interested in understanding the role of the neuroendocrine stress response in short- and long-term critical illness outcomes, and using this knowledge to develop treatments to help patients. This research includes an interest in the influence of circulating hormones on memories formed during illness and their relationship to PTSD outcomes, the role of inflammatory mediators in anxiety- and depression-like emotional states in survivors, and mechanistic approaches to tackle the syndrome of glucocorticoid resistance during critical illness.
-
Marsh JS, Teixeira C, Gavade S, Johnston C, Baranwal S, Snyder CN, Chang C-L, Yang S, Spencer-Segal JL. Psychoneuroendocrinology, 2024 Oct 30; 171: 107229Journal ArticleVentral subiculum control of avoidance behavior and hypothalamic-pituitary-adrenal axis reactivity via the bed nucleus of the stria terminalis in male and female mice - ISPNE 2024 Dirk Helhammer Award.
DOI:10.1016/j.psyneuen.2024.107229 PMID: 39504606 -
Ferone D, Freda P, Katznelson L, Gatto F, Kadioğlu P, Maffei P, Seufert J, Silverstein JM, Spencer-Segal JL, Isaeva E, Dreval A, Harrie M, Svedberg A, Tiberg F. J Clin Endocrinol Metab, 2024 Oct 8;Journal ArticleOctreotide subcutaneous depot for acromegaly: A randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1.
DOI:10.1210/clinem/dgae707 PMID: 39378125 -
Ferone D, Silverstein J, Freda P, Katznelson L, Gatto F, Kadioglu P, Maffei P, Seufert J, Spencer-Segal JL, Isaeva E, Dreval A, Harrie M, Svedberg A, Pedroncelli AM, Tiberg F. Journal of the Endocrine Society, 2024 Oct 5; 8 (Supplement_1): bvae163.1155Proceeding / Abstract / Poster7373 CAM2029, Octreotide Subcutaneous Depot, Provides Sustained Biochemical Control of Acromegaly: Interim Results From a Phase 3 Study (ACROINNOVA 2)
DOI:10.1210/jendso/bvae163.1155 -
Ferone D, Spencer-Segal JL, Yaylali GF, Doknic M, Isaeva E, Dreval A, Gilis-Januszewska A, Gezer E, Bancos I, Katznelson L, Harrie M, Svedberg A, Pedroncelli AM, Tiberg F. Journal of the Endocrine Society, 2024 Oct 5; 8 (Supplement_1): bvae163.1200Proceeding / Abstract / Poster7376 Efficacy and Safety of CAM2029 in Patients With Controlled or Inadequately Controlled Acromegaly on Standard-of-Care Treatment: Interim Data for the “New to CAM2029” Patient Subgroup in a Phase 3 Study (ACROINNOVA 2)
DOI:10.1210/jendso/bvae163.1200 -
Ferone D, Maffei P, Silverstein J, Spencer-Segal JL, Gilis-Januszewska A, Doknic M, Kadioglu P, Freda P, Katznelson L, Yaylali GF, Harrie M, Svedberg A, Pedroncelli AM, Tiberg F. Journal of the Endocrine Society, 2024 Oct 5; 8 (Supplement_1): bvae163.1154Proceeding / Abstract / Poster7377 CAM2029, Octreotide Subcutaneous Depot, Improves Patient-Reported Outcomes From Standard-of-Care Baseline in Patients With Acromegaly: Interim Results From a Phase 3 Study (ACROINNOVA 2)
DOI:10.1210/jendso/bvae163.1154 -
2024 Sep 12;PresentationDirk Helhammer Award Talk: Neural regulation of stress responses via the ventral subiculum and BNST
-
Silverstein J, Silverstein J, Ferone D, Freda P, Katznelson L, Gatto F, Kadioglu P, Maffei P, Seufert J, Spencer-Segal JL, Isaeva E, Dreval A, Harrie M, Svedberg A, Tiberg F. Endocrine Practice, 2024 May; 30 (5): s117 - s118.Proceeding / Abstract / Poster#1705024 A Randomized Phase 3 Trial to Assess Efficacy and Safety of a Novel Formulation of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
DOI:10.1016/j.eprac.2024.03.359 -
Chaudhuri D, Nei AM, Rochwerg B, Balk RA, Asehnoune K, Cadena R, Carcillo JA, Correa R, Drover K, Esper AM, Gershengorn HB, Hammond NE, Jayaprakash N, Menon K, Nazer L, Pitre T, Qasim ZA, Russell JA, Santos AP, Sarwal A, Spencer-Segal J, Tilouche N, Annane D, Pastores SM. Crit Care Med, 2024 May 1; 52 (5): e219 - e233.Journal Article2024 Focused Update: Guidelines on Use of Corticosteroids in Sepsis, Acute Respiratory Distress Syndrome, and Community-Acquired Pneumonia.
DOI:10.1097/CCM.0000000000006172 PMID: 38240492